SAREPTA THERAPEUTICS INC

NASDAQ: SRPT (Sarepta Therapeutics, Inc.)

Last update: 28 Feb, 12:08AM

16.76

-0.69 (-3.95%)

Previous Close 17.45
Open 17.17
Volume 2,613,898
Avg. Volume (3M) 2,846,139
Market Cap 1,756,233,216
Price / Earnings (Forward) 4.53
Price / Sales 0.780
Price / Book 1.58
52 Weeks Range
10.42 (-37%) — 107.77 (543%)
Earnings Date 6 May 2026
Profit Margin -11.12%
Operating Margin (TTM) -40.33%
Diluted EPS (TTM) -2.64
Quarterly Revenue Growth (YOY) 80.20%
Quarterly Earnings Growth (YOY) 248.40%
Total Debt/Equity (MRQ) 118.73%
Current Ratio (MRQ) 4.02
Operating Cash Flow (TTM) -547.15 M
Levered Free Cash Flow (TTM) -741.26 M
Return on Assets (TTM) -2.19%
Return on Equity (TTM) -23.61%

Market Trend

Short Term Medium Term
Industry Biotechnology (US) Bullish Mixed
Biotechnology (Global) Bullish Mixed
Stock Sarepta Therapeutics, Inc. Bullish Bearish

AIStockmoo Score

-2.1
Analyst Consensus 1.5
Insider Activity -3.5
Price Volatility -2.0
Technical Moving Averages -2.5
Technical Oscillators -4.0
Average -2.10

Similar Stocks

Stock Market Cap DY P/E (TTM) P/B
SRPT 2 B - - 1.58
RVMD 19 B - - 12.03
IONS 12 B - - 24.04
NUVL 8 B - - 6.31
ACLX 7 B - - 16.63
VKTX 4 B - - 6.42

Sarepta Therapeutics Inc is a biotechnology company focused on treating rare, infectious, and other diseases. It targets a broad range of diseases while focusing on the rapid development of its drug candidates. Sarepta's involves proprietary RNA-targeted technology platforms to be used for developing novel pharmaceutical products to treat a broad range of diseases and address key unmet medical needs. The company uses third-party contractors to manufacture its product candidates. Majority of company's product candidates are at an early stage of development.

Sector Healthcare
Industry Biotechnology
Investment Style Small Core
% Held by Insiders 4.42%
% Held by Institutions 96.33%
52 Weeks Range
10.42 (-37%) — 107.77 (543%)
Price Target Range
5.00 (-70%) — 38.00 (126%)
High 38.00 (Wells Fargo, 126.73%) Buy
Median 21.50 (28.28%)
Low 5.00 (HC Wainwright & Co., -70.17%) Sell
Average 21.50 (28.28%)
Total 2 Buy, 2 Sell
Avg. Price @ Call 17.97
Firm Date Target Price Call Price @ Call
Citigroup 10 Mar 2026 9.00 (-46.30%) Sell 17.66
HC Wainwright & Co. 02 Mar 2026 5.00 (-70.17%) Sell 16.32
27 Jan 2026 5.00 (-70.17%) Sell 22.17
Wells Fargo 27 Feb 2026 38.00 (126.73%) Buy 16.76
Wedbush 23 Jan 2026 34.00 (102.86%) Buy 21.13
Name Avg. Buy ($) Avg. Sell ($) Net Quantity Net Value ($)
ESTEPAN IAN MICHAEL - 17.61 -2,716 -47,844
MAYO STEPHEN - 17.04 -7,239 -123,353
RODINO-KLAPAC LOUISE - 17.61 -2,347 -41,344
ROTHFUSS CRISTIN - 17.61 -1,804 -31,764
WONG RYAN HO-YAN - 17.61 -531 -9,351
Aggregate Net Quantity -14,637
Aggregate Net Value ($) -253,657
Aggregate Avg. Buy ($) -
Aggregate Avg. Sell ($) 17.55
Name Holder Date Type Quantity Price Value ($)
MAYO STEPHEN Director 12 Mar 2026 Sell (-) 7,239 17.04 123,353
ROTHFUSS CRISTIN Officer 11 Mar 2026 Disposed (-) 974 17.58 17,123
RODINO-KLAPAC LOUISE Officer 11 Mar 2026 Disposed (-) 948 17.58 16,666
WONG RYAN HO-YAN Officer 11 Mar 2026 Disposed (-) 256 17.58 4,500
ESTEPAN IAN MICHAEL Officer 11 Mar 2026 Disposed (-) 1,097 17.58 19,285
ESTEPAN IAN MICHAEL Officer 09 Mar 2026 Disposed (-) 1,619 17.64 28,559
RODINO-KLAPAC LOUISE Officer 09 Mar 2026 Disposed (-) 1,399 17.64 24,678
ROTHFUSS CRISTIN Officer 09 Mar 2026 Disposed (-) 830 17.64 14,641
WONG RYAN HO-YAN Officer 09 Mar 2026 Disposed (-) 275 17.64 4,851

The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.

Portfolio

AI Template

Your price alert

Risk Profile

| | | | |
Conservative
Moderate Conservative
Moderate
Moderate Aggressive
Aggressive
Margin of Safety (EP)
Partial Profit (TP1)
Target Profit (TP2)
Maximum Loss (SL)

Disclaimer: The above is for illustrative purposes only and is NOT investment advice. Seek advice from a qualified financial professional.

Entry Price (EP)

Take Profit 1 (TP1)

Take Profit 2 (TP2)

Stop Loss (SL)

52W Range
 
52WL
 
52WH
SL
EP
TP1
TP2

All alert prices are within 52 weeks price range

Realized Profit -
Unrealized Profit -
Dividend Received 2026 -
Total Profit -
Avg. Return -
Quantity (Buy) -
Avg. Price (Buy) -
Quantity (Sold) -
Avg. Price (Sold) -
No stocks matching your criteria